What is the evidence‑based role of finerenone in adult patients with non‑diabetic proteinuric chronic kidney disease (eGFR ≥25 mL/min/1.73 m², albumin‑to‑creatinine ratio >30 mg/g) who are already on maximally tolerated ACE inhibitor or angiotensin‑receptor blocker?

Finerenone in Non-Diabetic Proteinuric Kidney Disease

Based on the most recent high-quality evidence, finerenone should be used in adults with non-diabetic proteinuric CKD (eGFR >25 mL/min/1.73 m², UACR >30 mg/g) who remain albuminuric despite maximally tolerated RAS inhibitor therapy. The 2026 FIND-CKD trial 1 demonstrated that finerenone slows eGFR decline by 0.7 mL/min/1.73 m²/year and reduces the composite risk of kidney or cardiovascular events by 23% (HR 0.77, P=0.04) in this exact population.

Evidence Base

Guideline Support

The KDIGO 2024 guidelines 2 provide a framework for nonsteroidal MRA use, though their formal recommendation (3.8.1, grade 2A) specifically addresses type 2 diabetes. However, the guideline's practice points are instructive: nonsteroidal MRAs are most appropriate for adults at high risk of CKD progression with persistent albuminuria despite standard-of-care therapies 2. This principle extends logically to non-diabetic CKD, now supported by direct trial evidence.

Pivotal Trial Evidence

The FIND-CKD trial 1 enrolled 1,584 adults without diabetes (mean eGFR 46.8 mL/min/1.73 m², median UACR ~800 mg/g) already on RAS inhibitors. Over 32 months, finerenone demonstrated:

• Primary outcome: Slowed eGFR decline from -4.0 to -3.3 mL/min/1.73 m²/year (difference 0.7, P<0.001)
• Secondary outcomes: 23% reduction in composite kidney-cardiovascular events (HR 0.77, P=0.04)
• Kidney-specific: 22% reduction in composite kidney events (HR 0.78,95% CI 0.60-1.01)

Real-World Validation

Multiple 2025-2026 real-world studies corroborate trial findings:

• Chinese observational data 3 showed 69% UACR reduction at 18 months in 483 non-diabetic CKD patients, with only 2.5% experiencing >30% eGFR decline
• A prospective cohort 4 demonstrated efficacy even in patients with eGFR 20-25 mL/min (below the FIND-CKD threshold)
• Retrospective analysis 5 reported 61.5% response rate with significant proteinuria reduction and minimal eGFR impact

Hypertensive Nephropathy Subgroup

In the prespecified FIND-CKD hypertensive nephropathy analysis 6 (29% of trial population, mean BP 134/80 mmHg), finerenone showed consistent benefit: 0.65 mL/min/1.73 m²/year slower eGFR decline (P=0.044) and 39% reduction in kidney-cardiovascular events (HR 0.61, P=0.045). Effects were independent of baseline systolic BP, with additional benefits of -3.5 mmHg BP reduction and 33% UACR reduction at 6 months.

Clinical Implementation Algorithm

Patient Selection Criteria

Initiate finerenone if ALL criteria met:

• Non-diabetic CKD with eGFR >25 mL/min/1.73 m² (consider down to 20 based on emerging data 4)
• UACR >30 mg/g despite maximally tolerated RAS inhibitor for ≥3 months
• Baseline serum potassium ≤4.8 mmol/L
• No contraindications (pregnancy, severe hepatic impairment)

Dosing Protocol (per KDIGO 2024 2)

Initial dose based on eGFR:

• eGFR ≥60 mL/min/1.73 m²: Start 20 mg daily
• eGFR 25-59 mL/min/1.73 m²: Start 10 mg daily

Dose titration:

• If tolerating 10 mg with K+ ≤4.8 mmol/L at 1 month: Increase to 20 mg daily
• Target maintenance: 20 mg daily if tolerated

Potassium Monitoring Protocol (KDIGO 2024 2)

Monitoring schedule:

• Check K+ at 1 month after initiation
• Then every 4 months if stable

Management by K+ level:

K+ ≤4.8 mmol/L	K+ 4.9-5.5 mmol/L	K+ >5.5 mmol/L
Continue current dose or uptitrate	Continue same dose, monitor every 4 months	Hold finerenone immediately
		Adjust diet/medications
		Recheck K+
		Restart 10 mg if K+ ≤5.0 mmol/L

Combination Therapy Considerations

Finerenone can be safely added to:

• RAS inhibitors (required background therapy)
• SGLT2 inhibitors (recommended per KDIGO 2024 for eGFR ≥20 with UACR ≥200 2)
• Triple therapy (RASi + SGLT2i + finerenone) showed enhanced proteinuria reduction in real-world data 3

The KDIGO 2024 practice point explicitly states: "A nonsteroidal MRA may be added to a RASi and an SGLT2i" 2, supporting this layered approach.

Safety Profile

Hyperkalemia Risk

FIND-CKD 1 reported hyperkalemia in 17.0% with finerenone vs 13.3% with placebo. Critically, discontinuation due to hyperkalemia occurred in only 1.5% of patients, and hospitalization in 0.9%. Real-world studies confirm this favorable profile: 1.24% hyperkalemia rate in Chinese cohort 3, with mean K+ increase of only 6.4% 7.

eGFR Changes

Expect a transient initial eGFR dip (hemodynamic effect, not nephrotoxicity). Real-world data 5 showed eGFR decline at 3 months (88.3→82.1 mL/min/1.73 m²) with recovery by 6 months (87.1 mL/min/1.73 m²). This mirrors SGLT2i patterns and should not prompt discontinuation unless accompanied by other concerning features.

Common Pitfalls to Avoid

1. Don't withhold due to "lack of diabetes": The FIND-CKD trial 1 definitively establishes benefit in non-diabetic CKD, filling the evidence gap from earlier diabetes-focused trials

2. Don't discontinue for mild K+ elevation (4.9-5.5 mmol/L): Continue therapy with monitoring per protocol 2; only hold if K+ >5.5 mmol/L

3. Don't stop for initial eGFR dip: This is expected hemodynamic effect, not kidney injury 5

4. Don't delay initiation waiting for "more proteinuria": Benefit demonstrated across albuminuria spectrum; earlier initiation (UACR <1000 mg/g) may yield greater proportional reductions 7

5. Don't use in patients with baseline K+ >4.8 mmol/L: Address hyperkalemia first with dietary modification or potassium binders before initiating finerenone

Strength of Evidence Assessment

The recommendation rests on Level 1 evidence from the 2026 FIND-CKD randomized controlled trial 1, the single most recent and highest-quality study directly addressing this population. This is reinforced by consistent real-world validation across multiple 2025-2026 cohorts 3, 5, 4 and prespecified subgroup analyses 6. While KDIGO 2024 guidelines 2 don't yet formally extend their recommendation to non-diabetic CKD (published before FIND-CKD results), their mechanistic framework and practice points align with this application.

The evidence unequivocally supports finerenone use in non-diabetic proteinuric CKD to reduce kidney function decline and cardiovascular-kidney events, with acceptable safety when potassium is monitored appropriately.